Plasma proprotein convertase subtilisin kexin type 9 is not altered in subjects with impaired glucose metabolism and type 2 diabetes mellitus, but its relationship with non-HDL cholesterol and apolipoprotein B may be modified by type 2 diabetes mellitus:

Brouwers, M. C. G. J., Troutt, J. S., van Greevenbroek, M. M. J., Ferreira, I., Feskens, E. J., van der Kallen, C. J. H., Schaper, N. C., Schalkwijk, C. G., Konrad, R. J. and Stehouwer, C. D. A. (2011) Plasma proprotein convertase subtilisin kexin type 9 is not altered in subjects with impaired glucose metabolism and type 2 diabetes mellitus, but its relationship with non-HDL cholesterol and apolipoprotein B may be modified by type 2 diabetes mellitus: the CODAM study. Atherosclerosis, 217 1: 263-267. doi:10.1016/j.atherosclerosis.2011.03.023


Author Brouwers, M. C. G. J.
Troutt, J. S.
van Greevenbroek, M. M. J.
Ferreira, I.
Feskens, E. J.
van der Kallen, C. J. H.
Schaper, N. C.
Schalkwijk, C. G.
Konrad, R. J.
Stehouwer, C. D. A.
Title Plasma proprotein convertase subtilisin kexin type 9 is not altered in subjects with impaired glucose metabolism and type 2 diabetes mellitus, but its relationship with non-HDL cholesterol and apolipoprotein B may be modified by type 2 diabetes mellitus: the CODAM study
Journal name Atherosclerosis   Check publisher's open access policy
ISSN 0021-9150
1879-1484
Publication date 2011-07
Year available 2011
Sub-type Article (original research)
DOI 10.1016/j.atherosclerosis.2011.03.023
Open Access Status Not yet assessed
Volume 217
Issue 1
Start page 263
End page 267
Total pages 5
Place of publication E Park, Shannon, Clare Ireland
Publisher Elsevier Ireland
Language eng
Formatted abstract
Objective: Type 2 diabetes mellitus (T2DM) is associated with elevated plasma apolipoprotein B and triglycerides levels, reduced HDL cholesterol and the presence of small-dense LDL particles. The present study was conducted to investigate the role of plasma proprotein convertase subtilisin kexin type 9 (PCSK9) levels, a regulator of LDL-receptor expression, in the occurrence of diabetic dyslipidemia.

Methods: Plasma PCSK9 was measured in a cohort of subjects with normal glucose metabolism (NGM; n= 288), impaired glucose metabolism (IGM; n= 121) and type 2 diabetes mellitus (T2DM; n= 139) to study whether its relation with plasma apolipoprotein B, triglycerides, total cholesterol, non-HDL cholesterol, LDL cholesterol and HDL cholesterol differed by levels of glucose metabolism status.

Results: Plasma PCSK9 levels were not different between the three groups (82, 82 and 80 ng/mL in NGM, IGM and T2DM, respectively). PCSK9 was positively associated with total cholesterol, non-HDL cholesterol, LDL cholesterol, apolipoprotein B and triglycerides levels in all subgroups. The regression slopes for the associations with non-HDL cholesterol were steeper among individuals with T2DM than with NGM (β= 0.016 versus β= 0.009, p-interaction = 0.05). Similar results were obtained for the relation with apolipoprotein B (β= 0.004 versus β= 0.002, p-interaction = 0.09).

Conclusions: Although glucose metabolism status per se is not associated with plasma PCSK9 levels, the presence of T2DM may modify the relation between plasma PCSK9 and non-HDL cholesterol and apolipoprotein B. These observations should be regarded as hypothesis generating for further studies aimed at elucidating the role of PCSK9 in the pathogenesis and treatment of diabetic dyslipidemia.
Keyword Diabetes mellitus
Dyslipidemia
Insulin resistance
PCSK9
Q-Index Code C1
Q-Index Status Provisional Code
Institutional Status Non-UQ

Document type: Journal Article
Sub-type: Article (original research)
Collection: School of Public Health Publications
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 21 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 23 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Tue, 19 May 2015, 18:52:31 EST by System User on behalf of Learning and Research Services (UQ Library)